As of Thursday close, Atara Biotherapeutics Inc.’s (NASDAQ:ATRA) stock was up $0.22, moving up 4.40 percent to $5.22. The average number of shares traded per day over the past five days has been 1,431,860 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.60 fall in that time frame. In the last twenty days, the average volume was 1,024,980, while in the previous 50 days, it was 1,070,366.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ATRA stock retreated -36.42%. Shares of the company fell to $4.84 on 05/12/22, the lowest level in the past month. A 52-week high of $20.04 was reached on 01/03/22 after having rallying from a 52-week low of $4.99. Since the beginning of this year, ATRA’s stock price has dropped by -66.88% or -$10.54, and marked a new high 1 time. However, the stock has declined by -73.95% since its 52-week high.
Atara Biotherapeutics Inc. (ATRA) last reported insider trading activity 73 days ago on Mar 01. Dupont Jakob, the EVP, Head of R&D of the company, disposed of 2,221 shares for $9.86 on Mar 01. It resulted in a $21,890 divestment by the insider. Koppikar Utpal sold 3,763 shares at an average price of $9.86 on Mar 01. The insider now owns 213,174 shares following the transaction. On Mar 01, SVP, GC & Secretary Murugan Amar sold 2,577 shares at $9.86 apiece. The transaction was valued at $25,400.
The stock’s beta is 1.92. Besides these, the trailing price-to-sales (P/S) ratio of 23.67, the price-to-book (PB) ratio of 2.34.
In the three months ended September 29, Atara Biotherapeutics Inc.’s quick ratio stood at 3.10, while its current ratio was 3.10, showing that the company is able to pay off its debt. Based on annual data, ATRA earned $360.8 million in gross profit and brought in $20.34 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ATRA’s revenue rose 51.44% to $7.55 million during the quarter, while net income inched up to $7.31 million. While analysts expected Atara Biotherapeutics Inc. to report -$0.94 quarterly earnings, the actual figure was -$0.9 per share, beating the consensus estimate by 4.30%. During the quarter, the company generated -$90.4 million in EBITDA. The liabilities of Atara Biotherapeutics Inc. were 188.51 million at the end of its most recent quarter ended September 29, and its total debt was $24.57 million. The value of shareholders’ equity is $93.1 million.
This quick technical analysis looks at Atara Biotherapeutics Inc.’s (ATRA) price momentum. With a historical volatility rate of 133.49%, the RSI 9-day stood at 25.92% on 12 May.
With respect to its five-day moving average, the current Atara Biotherapeutics Inc. price is down by -23.46% percent or -$1.60. At present, ATRA shares trade -37.93% below its 20-day simple moving average and -65.54% percent below its 100-day simple moving average. However, the stock is currently trading approximately -46.73% below its SMA50 and -60.42% below its SMA200.
Stochastic coefficient K was 8.65% and Stochastic coefficient D was 10.53%, while ATR was 0.69. Given the Stochastic reading of 15.02% for the 14-day period, the RSI (14) reading has been calculated as 27.82%. As of today, the MACD Oscillator reading stands at -0.99, while the 14-day reading stands at -1.15.
Atara Biotherapeutics Inc. downgraded its rating on Atara Biotherapeutics Inc. (NASDAQ: ATRA) to a Neutral in a note to investors on May 10, 2022. The analysts firm previously had a Buy rating on the stock.Atara Biotherapeutics Inc. (ATRA) has been rated Overweight by analysts. According to 1 brokerage firm, ATRA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Atara Biotherapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $23.50, the current consensus forecast for the stock is $5.00 – $67.00. Based on these forecasts, analysts predict Atara Biotherapeutics Inc. (ATRA) will achieve an average price target of $26.88.